• Publications
  • Influence
The relationship between paroxetine and the sparteine oxidation polymorphism
It is concluded that paroxetine and sparteine metabolism cosegregates, but the interphenotype difference in metabolism was less prominent at steady state than after a single dose, presumably because of saturation of thesparteine oxygenase (CYP2D6) in subjects who were extensive metabolizers.
A review of the metabolism and pharmacokinetics of paroxetine in man
Its metabolism and pharmacokinetics are to some degree affected by the induction or inhibition of drug metabolizing enzyme(s), and drug interactions involving paroxetine are considered unlikely to be a frequent occurrence.
The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist.
Granisetron is a novel specific 5-HT3 receptor antagonist whose effects have been evaluated in an extensive programme of volunteer studies and exhibited essentially linear kinetics over the dose range studied (30-300 micrograms/kg).
Paroxetine plasma levels: lack of correlation with efficacy or adverse events
A retrospective analysis of the available data on the relationship between plasma concentrations of paroxetine and efficacy and adverse events is described.
Penetration of amoxicillin and potassium clavulanate into the cerebrospinal fluid of patients with inflamed meninges
Levels suggest that the amoxicillin-potassium clavulanate combination may be effective for the treatment of bacterial meningitis caused by beta-lactamase-producing pathogens.
Pharmacokinetics of intravenous amoxycillin and potassium clavulanate in seriously ill children.
The data suggest that the treatment of some infections due to beta-lactamase producing organisms in such severely ill children may require more frequent iv administration of amoxycillin and potassium clavulanate, than in less severely affected children.
Metabolism and disposition of 14C-granisetron in rat, dog and man after intravenous and oral dosing.
The disposition and metabolic fate of 14C-granisetron, a novel 5-HT3 antagonist, was studied in rat, dog, and male human volunteers after intravenous and oral administration and there were no sex-specific differences observed in radiometabolite patterns in rat or dog.
Late breaking abstracts